"MG-63人骨肉瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長(zhǎng)速率、鋪板效率、生長(zhǎng)條件和生長(zhǎng)特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長(zhǎng)的快速生長(zhǎng)細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長(zhǎng)期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過(guò)程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長(zhǎng)期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長(zhǎng)。

換液周期：每周2-3次

H-1666 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng)，松散;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：OCI-AML-2細(xì)胞、BE(2)M-17細(xì)胞、HCC1428細(xì)胞

MCF.10A Cells;背景說(shuō)明：乳腺；上皮細(xì)胞；自發(fā)永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HEP-3B2細(xì)胞、P1-Raji細(xì)胞、F442A細(xì)胞

P3HR1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：SNU119細(xì)胞、KYSE 450細(xì)胞、Clone 166細(xì)胞

背景信息：該細(xì)胞源自１４歲患有骨肉瘤的白人男性；聚次黃嘌呤核苷-聚胞嘧啶核苷、和D可以誘導(dǎo)產(chǎn)生高水平的干擾素。該細(xì)胞表達(dá)TGF-β受體Ⅰ和Ⅱ。

MG-63人骨肉瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測(cè)；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺(tái)，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長(zhǎng)特性和后續(xù)的實(shí)驗(yàn)需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長(zhǎng)的比較快，不是著急用的話，我就會(huì)按1E6個(gè)細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會(huì)適當(dāng)多傳一點(diǎn)；還可通過(guò)顯微鏡計(jì)數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實(shí)驗(yàn)。

624-mel Cells;背景說(shuō)明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HSC-5 [Human skin squamous cell carcinoma]細(xì)胞、aNK細(xì)胞、NUGC-2細(xì)胞

HuH-6 Cells;背景說(shuō)明：肝癌。據(jù)說(shuō)產(chǎn)球蛋白和甲胎蛋白。;傳代方法：消化３-５分鐘。１：２。６-７天長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：CEM-C7細(xì)胞、4-1st細(xì)胞、M-1 myeloid leukemia細(xì)胞

HeLaS3 Cells;背景說(shuō)明：該細(xì)胞是１９５５年由PuckTT,MarcusPI和CieciuraSJ建系的，含HPV-１８序列；角蛋白陽(yáng)性；可用于與染色體突變、細(xì)胞營(yíng)養(yǎng)、集落形成相關(guān)的哺乳動(dòng)物細(xì)胞的克隆分析。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KP-N-RT-BM細(xì)胞、HCC0202細(xì)胞、AC29細(xì)胞

7.16.4 Cells(提供STR鑒定圖譜)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

物種來(lái)源：人源、鼠源等其它物種來(lái)源

MG-63人骨肉瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

形態(tài)特性：成纖維細(xì)胞樣

貼壁細(xì)胞消化傳代時(shí)通常采用兩種方法：一、加入胰酶等細(xì)胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細(xì)胞始脫落時(shí)，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對(duì)細(xì)胞施加胰酶選擇，因?yàn)榭偸琴N壁不牢的細(xì)胞先脫落，對(duì)腫瘤細(xì)胞來(lái)說(shuō)，這部分細(xì)胞有可能是惡性程度較GAO的細(xì)胞亞群。一種簡(jiǎn)單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細(xì)胞消化的難易程度)，棄之，這樣依賴(lài)殘余的胰酶就可將細(xì)胞消化單細(xì)胞。對(duì)于較難消化的細(xì)胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對(duì)細(xì)胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點(diǎn)，直接加酶消化應(yīng)該不會(huì)有什么問(wèn)題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預(yù)熱)總體積１/１０v。消化到有細(xì)胞脫落。不過(guò)有人說(shuō)EDA對(duì)細(xì)胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡(jiǎn)單、省事；效果很HAO并且不損失細(xì)胞！

HuPT4 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MC-38細(xì)胞、Loucy細(xì)胞、SJSA1細(xì)胞

H23 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代；３-４天１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：EC-GI細(xì)胞、HUSMC細(xì)胞、2T細(xì)胞

H889 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：MDAMB415細(xì)胞、MDA.MB.435細(xì)胞、Ramos 2G6 4C10細(xì)胞

D6P2T Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：５—１：１０傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：神經(jīng)元 ;相關(guān)產(chǎn)品有：HFL1細(xì)胞、SAS細(xì)胞、Hs 675.T細(xì)胞

KRC/Y Cells;背景說(shuō)明：腎透明細(xì)胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：VMM5細(xì)胞、GT1-1細(xì)胞、P31/FUJ細(xì)胞

MILE SVEN1 Cells;背景說(shuō)明：MS１是１９９４年建株的胰島內(nèi)皮細(xì)胞株。原代培養(yǎng)的胰島內(nèi)皮細(xì)胞用抗G４１８的溫度敏感型SV４０大T抗原(tsA-５８-３)轉(zhuǎn)染。抗性克隆用克隆環(huán)分離，并篩選吸收dil-Ac-LDL的。這株細(xì)胞保留了內(nèi)皮細(xì)胞的許多特性，如吸收乙?；疞DL和表達(dá)八因子相關(guān)抗原及BEGF受體。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：3T3-A31細(xì)胞、HuH7細(xì)胞、IFRS1細(xì)胞

MOLT3 Cells;背景說(shuō)明：急性T淋巴細(xì)胞白血?。荒行?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H660細(xì)胞、P3 (Jiyoye)細(xì)胞、293 c18細(xì)胞

DoTc2-4510 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MS-751細(xì)胞、RPMI no. 8226細(xì)胞、SG231細(xì)胞

COLO 824 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：KY-270細(xì)胞、NP-69細(xì)胞、HEK293-EBNA細(xì)胞

TNC-1B12B4 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Pa18C細(xì)胞、G-402細(xì)胞、U373MG細(xì)胞

SUIT2 Cells;背景說(shuō)明：胰腺管癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：rRMECs細(xì)胞、PG-4(S+L-)細(xì)胞、CHO Lec1細(xì)胞

NCTC 929 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Panc02.03細(xì)胞、HPMEC細(xì)胞、S3 HeLa細(xì)胞

Panc-05.04 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SW 1353細(xì)胞、WEHI164細(xì)胞、EVSA/T細(xì)胞

NK-92.05 Cells;背景說(shuō)明：NK細(xì)胞；淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：32D-Cl3細(xì)胞、H1573細(xì)胞、NCI-H146細(xì)胞

FTC-133 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SNU-C1細(xì)胞、SNU-251細(xì)胞、NSC34細(xì)胞

MDCKII Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代，３-４天傳１次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H774細(xì)胞、EoL-1-cell細(xì)胞、HCE細(xì)胞

Huh-7 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MCM細(xì)胞、EAhy926細(xì)胞、MDAMB435S細(xì)胞

Abcam HEK293T DESI1 KO Cells(提供STR鑒定圖譜)

AG09904 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line NPX316 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC514 Cells(提供STR鑒定圖譜)

BT-474-Luc2 Cells(提供STR鑒定圖譜)

COS-M5 Cells(提供STR鑒定圖譜)

DA04040 Cells(提供STR鑒定圖譜)

DT40-PRKDC(-/-)-XRCC6(-/-) Cells(提供STR鑒定圖譜)

GM04017 Cells(提供STR鑒定圖譜)

PANC-02-03 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HEK-293-EBNA細(xì)胞、MSTO211H細(xì)胞、MeWo細(xì)胞

KYSE180 Cells;背景說(shuō)明：食管鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RSC-96細(xì)胞、SU4細(xì)胞、JROECL21細(xì)胞

SUM 190PT Cells;背景說(shuō)明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LS174T細(xì)胞、HeLaS3細(xì)胞、NE-1細(xì)胞

COV434 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SRS-82細(xì)胞、NWA細(xì)胞、FL83B細(xì)胞

D283 Med Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮細(xì)胞的多細(xì)胞聚集體，和一些貼壁 Cells;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：253JB-V細(xì)胞、L 428細(xì)胞、BC3H1細(xì)胞

C3A Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：TCC-SUP細(xì)胞、GAK細(xì)胞、CII細(xì)胞

SN-12C Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：２x１０^４ cells/ml;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：BRL 3A細(xì)胞、KM.12細(xì)胞、MCF7細(xì)胞

LAD-2 Cells;背景說(shuō)明：肥大 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：293FT細(xì)胞、PLC-PRF-5細(xì)胞、TB1 Lu細(xì)胞

MG-63人骨肉瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

MDCC MSB1 Cells;背景說(shuō)明：淋巴瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MLA-144細(xì)胞、DoTc2-4510細(xì)胞、Porcine Kidney-13細(xì)胞

SUM149 Cells;背景說(shuō)明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：KBM7細(xì)胞、PA317細(xì)胞、SP-2/0-AG14細(xì)胞

NCI-H1836 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：GRSL細(xì)胞、WM 266-4細(xì)胞、Jurkat 77細(xì)胞

Japanese Tissue Culture-28 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HuH-28細(xì)胞、Pa18C細(xì)胞、Molm14細(xì)胞

Me-Wo Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長(zhǎng)特性：混合生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：CEM細(xì)胞、HO1-N-1細(xì)胞、SW837細(xì)胞

Me-Wo Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長(zhǎng)特性：混合生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：CEM細(xì)胞、HO1-N-1細(xì)胞、SW837細(xì)胞

Hs 888.Lu Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HT細(xì)胞、PL12細(xì)胞、P3J細(xì)胞

GM25952 Cells(提供STR鑒定圖譜)

HAP1 NT5C3A (-) 1 Cells(提供STR鑒定圖譜)

C57 Mouse Tumor 64 Cells;背景說(shuō)明：肺腺癌；雌性；C５７;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BALB/3T3細(xì)胞、MDAPCa2b細(xì)胞、RT-4細(xì)胞

Ca761 Cells;背景說(shuō)明：乳腺癌；雌性；６１５;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH2170細(xì)胞、ST細(xì)胞、PTK 1細(xì)胞

KYSE-450 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MHHCALL2細(xì)胞、LA-N-1細(xì)胞、SW480細(xì)胞

WiDr/S Cells;背景說(shuō)明：結(jié)腸癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：WERI-Rb1細(xì)胞、MDCK (NBL-2)細(xì)胞、Hs-343-T細(xì)胞

190PT Cells;背景說(shuō)明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs 888.T細(xì)胞、OCM1A細(xì)胞、Calu 3細(xì)胞

OE-19 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Nthy-ori 3.1細(xì)胞、CTLA4Ig-24細(xì)胞、JM-1細(xì)胞

HCC0038 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：U-373MG細(xì)胞、Hs688(A)T細(xì)胞、J-774細(xì)胞

ESC-410 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HOS-143B細(xì)胞、FOXNY細(xì)胞、HANK-1細(xì)胞

Hs 444(A).T Cells(提供STR鑒定圖譜)

KML1-7 Cells(提供STR鑒定圖譜)

MLE-15 Cells(提供STR鑒定圖譜)

NSI002-B Cells(提供STR鑒定圖譜)

Reg4-G7 Cells(提供STR鑒定圖譜)

Ubigene Hep 3B2.1-7 NR1H4 KO Cells(提供STR鑒定圖譜)

XR-V11B Cells(提供STR鑒定圖譜)

HEK293T AGA KO Cells(提供STR鑒定圖譜)

Madin Darby Bovine Kidney Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LU65細(xì)胞、JB6 [Mouse]細(xì)胞、H1623細(xì)胞

58F Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BNL CL2細(xì)胞、H1395細(xì)胞、NCI-H2135細(xì)胞

KYSE520 Cells;背景說(shuō)明：食管鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：TE-85細(xì)胞、Lewis lung carcinoma細(xì)胞、LC-2 ad細(xì)胞

HT1197 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：５-１：１０傳代，２天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：190PT細(xì)胞、MKN1細(xì)胞、A-375細(xì)胞

D341Med Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：髓母細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-H2405細(xì)胞、U20S細(xì)胞、MDA-MB-157細(xì)胞

D341Med Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：髓母細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-H2405細(xì)胞、U20S細(xì)胞、MDA-MB-157細(xì)胞

P388.D1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SKHEP1細(xì)胞、BT 549細(xì)胞、U-87MG ATCC細(xì)胞

tdott Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１０^５ cells/６０mm dish;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：PANC0813細(xì)胞、PC-3M-2B4細(xì)胞、U-2932細(xì)胞

NCI-SNU-C2B Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：X63-Ag8細(xì)胞、SUM 52細(xì)胞、GL261細(xì)胞

Turbot Embryonic Cell line Cells;背景說(shuō)明：胸腺；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RAOEC細(xì)胞、SKNEP細(xì)胞、Caco-2/BBe細(xì)胞

DanG Cells;背景說(shuō)明：胰腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：207細(xì)胞、TGW細(xì)胞、T2(174 x CEM.T2)細(xì)胞

Dami Cells;背景說(shuō)明：從一個(gè)巨核細(xì)胞白血病患者的血液建立了一株新的人類(lèi)巨核細(xì)胞(Dami)。 此細(xì)胞懸浮生長(zhǎng)為主，倍增時(shí)間２４-３０小時(shí)。 至少８９%的細(xì)胞可與血小板糖蛋白(GP) lb and Ilb/llla及血型糖蛋白單克隆抗體反應(yīng)。 不與抗淋巴腺、單核細(xì)胞、粒性白細(xì)胞、巨噬細(xì)胞抗原的抗體反應(yīng)。 Dami細(xì)胞為研究巨核細(xì)胞生化及分化提供了極好的模型。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮為主，少量貼壁;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：H-1954細(xì)胞、SK-NMC細(xì)胞、U-138MG細(xì)胞

Rh30 Cells;背景說(shuō)明：肺泡橫紋肌肉瘤；骨髓轉(zhuǎn)移;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HT 115細(xì)胞、Ramos.G6.C10細(xì)胞、JM-Jurkat細(xì)胞

Jiyoye(P-2003) Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：Cloudman S91 melanoma clone M-3細(xì)胞、ECC1細(xì)胞、Tb 1 Lu (NBL-12)細(xì)胞

T-ALL 1 Cells;背景說(shuō)明：該細(xì)胞源于一名復(fù)發(fā)T-ALL（急性T淋巴細(xì)胞性白血?。┑膬和耐庵苎?；具有很強(qiáng)的細(xì)胞毒性，體內(nèi)體外實(shí)驗(yàn)中都能破壞腫瘤細(xì)胞；IL-２可使細(xì)胞更好地生長(zhǎng)；α/β TCR陽(yáng)性，γ/δ TCR陰性；可產(chǎn)生IFNγ、TNF-α和GM-CSF。;傳代方法：維持細(xì)胞密度在４×１０５-１×１０６ cells/ml之間，２-３天換液１次　;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：ZR75-30細(xì)胞、NUGC-3細(xì)胞、OCI-Ly 19細(xì)胞

STBCi096-A Cells(提供STR鑒定圖譜)

NCIH2081 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：隨細(xì)胞的密度而增加;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：74Int細(xì)胞、HPAFII細(xì)胞、Homo sapiens No. 578, breast cells細(xì)胞

MN-9D Cells;背景說(shuō)明：多巴胺能神經(jīng)元 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Mono Mac6細(xì)胞、BT549細(xì)胞、H-2405細(xì)胞

HS-68 Cells;背景說(shuō)明：該細(xì)胞１９６９年由Owens RB建立。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HCC-1438細(xì)胞、CCD-112 CoN細(xì)胞、ChaGo-K-1細(xì)胞

D341 Med Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：髓母細(xì)胞樣;相關(guān)產(chǎn)品有：A172細(xì)胞、ZR-75-30細(xì)胞、Doubling time: ~50 hours (ATCC).細(xì)胞

SCL-I Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：WM-266-4細(xì)胞、UCLA-SO-M20細(xì)胞、NCI-H647細(xì)胞

MOLP2 Cells;背景說(shuō)明：骨髓瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA231細(xì)胞、Panc2.03細(xì)胞、PTK1細(xì)胞

H-226 Cells;背景說(shuō)明：１９８０年分離建立。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RSC96細(xì)胞、CAL 62細(xì)胞、NCI-H28細(xì)胞

Panc 04.03 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Mono-Mac-1細(xì)胞、T2(174 x CEM.T2)細(xì)胞、L428細(xì)胞

MG-63人骨肉瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

H-1882 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：IPECJ2細(xì)胞、K7M2細(xì)胞、MIA PaCa-2細(xì)胞

PE CA PJ34 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-716細(xì)胞、SW 1417細(xì)胞、Lu-65細(xì)胞

TALL-104 Cells;背景說(shuō)明：急性T淋巴細(xì)胞白血?。荒行?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Mino細(xì)胞、H676B細(xì)胞、HCEC-B4G12細(xì)胞

Ca-Ski Cells;背景說(shuō)明：這株細(xì)胞是從小腸腸系膜轉(zhuǎn)移灶的細(xì)胞中建立的。 據(jù)報(bào)道，它含有完整的HPV-１６(每個(gè)細(xì)胞大約６００個(gè)拷貝)和HPV-１８相關(guān)序列。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：LIM1215細(xì)胞、Ontario Cancer Institute-Acute Myeloid Leukemia-2細(xì)胞、ZR-75-30細(xì)胞

QG56 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MX1細(xì)胞、TC7細(xì)胞、Nb 2細(xì)胞

MESSADX5 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：８?jìng)鞔?；每周?３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣　;相關(guān)產(chǎn)品有：NCI-SNU-387細(xì)胞、HB611細(xì)胞、SPDC-CCL141細(xì)胞

BayGenomics ES cell line RRD121 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XE871 Cells(提供STR鑒定圖譜)

DAP-3DPw2 Cells(提供STR鑒定圖譜)

ML129-2G11.3B1 Cells(提供STR鑒定圖譜)

t1E4 Cells(提供STR鑒定圖譜)

LuCa2 Cells(提供STR鑒定圖譜)

" "PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990; PMCID=PMC361354

Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.

p53 functions as a cell cycle control protein in osteosarcomas.

Mol. Cell. Biol. 10:5772-5781(1990)

PubMed=1577731; DOI=10.1016/S0021-9258(19)50371-4

Bonewald L.F., Kester M.B., Schwartz Z., Swain L.D., Khare A., Johnson T.L., Leach R.J., Boyan B.D.

Effects of combining transforming growth factor beta and 1,25-dihydroxyvitamin D3 on differentiation of a human osteosarcoma (MG-63).

J. Biol. Chem. 267:8943-8949(1992)

PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0

Clover J., Gowen M.

Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?

Bone 15:585-591(1994)

PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X

Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.

Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.

Hum. Pathol. 27:408-416(1996)

PubMed=9144345; DOI=10.1359/jbmr.1997.12.5.786

Carmeliet G., Nys G., Bouillon R.

Microgravity reduces the differentiation of human osteoblastic MG-63 cells.

J. Bone Miner. Res. 12:786-794(1997)

PubMed=9600771; DOI=10.1016/S8756-3282(98)00007-6

Carmeliet G., Nys G., Stockmans I., Bouillon R.

Gene expression related to the differentiation of osteoblastic cells is altered by microgravity.

Bone 22:139S-143S(1998)

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4

Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.

Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.

Cancer Genet. Cytogenet. 140:145-152(2003)

PubMed=15736406

Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S.

Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.

Anticancer Res. 24:3743-3748(2004)

PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003

Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.

Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.

Cancer Genet. Cytogenet. 179:52-61(2007)

PubMed=19160414; DOI=10.1002/jcp.21667

Di Fiore R., Santulli A., Drago-Ferrante R., Giuliano M., De Blasio A., Messina C., Pirozzi G., Tirino V., Tesoriere G., Vento R.

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-amino treatment.

J. Cell. Physiol. 219:301-313(2009)

PubMed=19363654; DOI=10.1007/s10585-009-9259-6

Su Y.-X., Luo X.-J., He B.-C., Wang Y., Chen L., Zuo G.-W., Liu B., Bi Y., Huang J.-Y., Zhu G.-H., He Y., Kang Q., Luo J.-Y., Shen J.-K., Chen J., Jin X.-Q., Haydon R.C., He T.-C., Luu H.H.

Establishment and characterization of a new highly metastatic human osteosarcoma cell line.

Clin. Exp. Metastasis 26:599-610(2009)

PubMed=19787792; DOI=10.1002/gcc.20717

Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

Genes Chromosomes Cancer 49:40-51(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=21519327; DOI=10.1038/labinvest.2011.72

Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.

Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.

Lab. Invest. 91:1195-1205(2011)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23144859; DOI=10.1371/journal.pone.0048262; PMCID=PMC3492335

Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.

Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

PLoS ONE 7:E48262-E48262(2012)

PubMed=23129384; DOI=10.1002/jcp.24272

Di Fiore R., Fanale D., Drago-Ferrante R., Chiaradonna F., Giuliano M., De Blasio A., Amodeo V., Corsini L.R., Bazan V., Tesoriere G., Vento R., Russo A.

Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness.

J. Cell. Physiol. 228:1189-1201(2013)

PubMed=24903274; DOI=10.1096/fj.14-249714; PMCID=PMC5395736

Guignandon A., Faure C., Neutelings T., Rattner A., Mineur P., Linossier M.-T., Laroche N., Lambert C.A., Deroanne C., Nusgens B.V., Demets R., Colige A., Vico L.

Rac1 GTPase silencing counteracts microgravity-induced effects on osteoblastic cells.

FASEB J. 28:4077-4087(2014)

PubMed=25382592; DOI=10.1021/pr500907d

Lamego I., Duarte I.F., Marques M.P.M., Gil A.M.

Metabolic markers of MG-63 osteosarcoma cell line response to doxorubicin and methotrexate treatment: comparison to cisplatin.

J. Proteome Res. 13:6033-6045(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26320182; DOI=10.18632/oncotarget.5177; PMCID=PMC4745740

Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P.S., Khanna C.

Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.

Oncotarget 6:29469-29481(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29334376; DOI=10.1038/nm.4475; PMCID=PMC5803371

Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Nat. Med. 24:176-185(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)"